Momentus Raises $76M, Buys Time but Does Not Fix Fundamentals

What happened

Momentus announced it raised $76M in cash and progressed its Vigoride 7 mission. This capital injection alleviates near-term liquidity concerns but comes after months of dilutive financing and repeated going-concern warnings. The company's revenue remains negligible at ~$1M annualized against operating expenses of ~$20M, and the cash raise likely involved significant dilution. While the mission progress is a positive technical validation, it does not alter the structural deficit between revenue and cash burn. In our view, the equity still skews heavily toward downside risk, as the company remains dependent on a single financing source and faces delisting risk.

Implication

The capital raise buys 6-12 months of runway at current burn rates, but without a material revenue inflection, the company will need further dilutive financing. Our bear case remains more likely than the bull case, and we continue to recommend avoiding MNTS equity.

Thesis delta

The news does not alter our STRONG SELL rating. The capital raise extends the timeline but does not address the core issue of sub-scale revenue and negative equity. We maintain our view that the equity is worth near-zero absent a transformative contract or acquisition.